Cynthia Ma
Duke University - Duke Cancer Institute LAO · Washington University School of Medicine · Mayo Clinic Cancer Center P2C
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
10
all conditions, ClinicalTrials.gov
NIH grants tied to them
4
54 more share only the name and are not shown
Trial papers in breast cancer
60
PubMed author-name match
Trials
Studies that name Cynthia Ma as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:00 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03377101 · Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast CancerNational Cancer Institute (NCI) · withdrawn · Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive · principal investigator
- Ph3NCT01953588 · Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing SurgeryAlliance for Clinical Trials in Oncology · active not recruiting · Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma · study chair
- Ph2NCT01776008 · Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast CancerNational Cancer Institute (NCI) · terminated · Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma · principal investigator
- Ph2NCT01757327 · LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast CancerWashington University School of Medicine · withdrawn · Breast Neoplasms · principal investigator
- Ph2NCT01670877 · Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast CancerWashington University School of Medicine · completed · Breast Neoplasms · principal investigator
- Ph2NCT01557764 · Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast CancerWashington University School of Medicine · withdrawn · Breast Neoplasms · principal investigator
- Ph1NCT01344031 · MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast CancerNational Cancer Institute (NCI) · completed · Estrogen Receptor Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma · principal investigator
- Ph1NCT01339442 · BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast CancerWashington University School of Medicine · completed · Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer · principal investigator
- Ph1/Ph2NCT00699491 · Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast CancerNational Cancer Institute (NCI) · completed · Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7 · principal investigator
- Ph2NCT00263198 · PTK and Letrozole in Post-menopausal Women With Advanced Breast CancerWashington University School of Medicine · terminated · Breast Neoplasms · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 54 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Regulation of resistance to CDK4/6 inhibitor in breast cancerR01CA275904 · NCI · GEORGE WASHINGTON UNIVERSITY · fiscal years 2023 to 2026 · $633,959 awarded in 2026Same name and institution; not confirmed by an ID
- Research Project 1U54CA224083 · NCI · WASHINGTON UNIVERSITY · fiscal years 2017 to 2026 · $209,925 awarded in 2026Same name and institution; not confirmed by an ID
- Washington University Co-Clinical Imaging Research ResourceU24CA209837 · NCI · WASHINGTON UNIVERSITY · fiscal years 2022 to 2026 · $645,323 awarded in 2026Same name and institution; not confirmed by an ID
- FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancerR01CA273194 · NCI · WASHINGTON UNIVERSITY · fiscal years 2022 to 2025 · $1,254,028 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)UM1CA186704 · NCI · DUKE UNIVERSITY · PI JAMES L. ABBRUZZESE, ELIZABETH CLAIRE DEES, Andrea Wang-Gillam · fiscal years 2019Named on NCT03377101
- U10CA031946RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01953588
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2019 to 2026Named on NCT01776008
- Tissue Procurement CoreP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI Mark A. Watson · fiscal years 2019 to 2026Named on NCT01344031
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2019 to 2026Named on NCT00699491
- U10CA025224RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00699491
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:00 UTC. The ranking covers the 200 most relevant of 60 PubMed records, and a shared surname and initials can bring in a namesake. All 60 on PubMed
- TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.J Clin Oncol · 2012419 citationsRCR 10.3
- NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.Clin Cancer Res · 2017311 citationsRCR 8.9
- 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.Clin Cancer Res · 2017306 citationsRCR 11.4
- 275 citationsRCR 7.9
- Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.Lancet Oncol · 2010228 citationsRCR 5.0
- Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer.J Immunol · 2012179 citationsRCR 4.0
- First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.N Engl J Med · 2025177 citationsRCR 36.0
- Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.Clin Cancer Res · 2017167 citationsRCR 4.6
- 148 citationsRCR 9.2
- Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).Clin Cancer Res · 2021114 citationsRCR 5.5